Methods for sustained drug delivery and compositions useful therefor
AssigneeCentocor, Inc.
InventorsRobert E. Jordan, David M. Knight
Life of this patent
Estimating the term…
Abstract
Methods for sustained delivery of a therapeutic agent to the circulation of a patient are disclosed. Also disclosed are methods of preparing bioconjugates for sustained delivery of a therapeutic agent to the circulation of a patient.
Claims33
A method for sustained delivery of a therapeutic agent to the circulation of a patient comprising administering to the patient a predetermined effective amount of a bioconjugate, the bioconjugate comprising a binding moiety which selectively binds to a suspended formed element of the blood and the therapeutic agent, wherein the binding moiety is a chimeric 7E3 antibody or an antigen-binding fragment thereof and the therapeutic agent is not a thrombolytic agent.
A method for sustained delivery of a therapeutic agent to the circulation of a patient comprising administering to the patient a predetermined effective amount of a bioconjugate, the bioconjugate comprising a binding moiety which selectively binds to a suspended formed element of the blood and the therapeutic agent, wherein the binding moiety is a chimeric 7E3 Fab or Fab′ fragment and the therapeutic agent is not a thrombolytic agent.
A method for sustained delivery of a therapeutic agent to the circulation of a patient comprising administering to the patient a predetermined effective amount of a bioconjugate, the bioconjugate comprising a binding moiety which selectively binds to a suspended formed element of the blood and the therapeutic agent, wherein the binding moiety is an antibody or antigen-binding fragment thereof having specificity for glycoprotein IIb/IIIa, said antibody or fragment having the epitopic specificity of murine monoclonal antibody 7E3, and the therapeutic agent is not a thrombolytic agent.
A method for sustained delivery of a therapeutic agent to the circulation of a patient comprising the steps of:
- a) administering to the patient a predetermined effective amount of a first bioconjugate comprising a binding moiety which selectively binds to a suspended formed element of the blood and a capture moiety, wherein said binding moiety is a chimeric 7E3 antibody or an antigen-binding fragment thereof and said capture moiety comprises a binding site for a complementary binding partner;
- and
- b) administering to the patient a predetermined effective amount of a second bioconjugate comprising a complementary binding partner and a therapeutic agent,
- whereby sustained delivery of said therapeutic agent to the circulation of said patient occurs.
A method for sustained delivery of a therapeutic agent to the circulation of a patient comprising the steps of:
- a) administering to the patient a predetermined effective amount of a first bioconjugate comprising a binding moiety which selectively binds to a suspended formed element of the blood and a capture moiety, wherein said binding moiety is a chimeric 7E3 Fab or Fab′ fragment and said capture moiety comprises a binding site for a complementary binding partner;
- and
- b) administering to the patient a predetermined effective amount of a second bioconjugate comprising a complementary binding partner and a therapeutic agent,
- whereby sustained delivery of said therapeutic agent to the circulation of said patient occurs.
A method for sustained delivery of a therapeutic agent to the circulation of a patient comprising the steps of:
- a) administering to the patient a predetermined effective amount of a first bioconjugate comprising a binding moiety which selectively binds to a suspended formed element of the blood and a capture moiety, wherein said binding moiety is an antibody or antigen-binding fragment thereof having specificity for glycoprotein IIb/IIIa, said antibody or fragment having the epitopic specificity of murine monoclonal antibody 7E3, and said capture moiety comprises a binding site for a complementary binding partner;
- and
- b) administering to the patient a predetermined effective amount of a second bioconjugate comprising a complementary binding partner and a therapeutic agent,
- whereby sustained delivery of said therapeutic agent to the circulation of said patient occurs.
A method of preparing a bioconjugate for sustained delivery of a therapeutic agent to the circulation of a patient comprising the steps of:
- a) conjugating a binding moiety which selectively binds to a suspended formed element of the blood to the therapeutic agent, wherein said binding moiety is a chimeric 7E3 antibody or an antigen-binding fragment thereof, thereby producing a bioconjugate;
- and
- b) screening said bioconjugate for sustained delivery of the therapeutic agent,
- whereby a bioconjugate for sustained delivery of said therapeutic agent to the circulation of a patient is produced.
A method of preparing a bioconjugate for sustained delivery of a therapeutic agent to the circulation of a patient comprising the steps of:
- a) conjugating a binding moiety which selectively binds to a suspended formed element of the blood to the therapeutic agent, wherein said binding moiety is a chimeric 7E3 Fab or Fab′ fragment, thereby producing a bioconjugate;
- and
- b) screening said bioconjugate for sustained delivery of the therapeutic agent,
- whereby a bioconjugate for sustained delivery of said therapeutic agent to the circulation of a patient is produced.
A method of preparing a bioconjugate for sustained delivery of a therapeutic agent to the circulation of a patient comprising the steps of:
- a) conjugating a binding moiety which selectively binds to a suspended element of the blood to the therapeutic agent, wherein said binding moiety is an antibody or antigen-binding fragment thereof having specificity for glycoprotein IIb/IIIa, said antibody or fragment having the epitopic specificity of murine monoclonal antibody 7E3, thereby producing a bioconjugate;
- and
- b) screening said bioconjugate for sustained delivery of the therapeutic agent,
- whereby a bioconjugate for sustained delivery of said therapeutic agent to the circulation of a patient is produced.
A bioconjugate suitable for sustained delivery of a therapeutic agent to the circulation of a patient comprising a binding moiety which selectively binds to a suspended formed element of the blood and the therapeutic agent, wherein the binding moiety is a chimeric 7E3 antibody or an antigen-binding fragment thereof and the therapeutic agent is not a thrombolytic agent.
A bioconjugate suitable for sustained delivery of a therapeutic agent to the circulation of a patient comprising a binding moiety which selectively binds to a suspended formed element of the blood and the therapeutic agent, wherein the binding moiety is a chimeric 7E3 Fab or Fab′ fragment and the therapeutic agent is not a thrombolytic agent.
A bioconjugate suitable for sustained delivery of a therapeutic agent to the circulation of a patient comprising a binding moiety which selectively binds to a suspended formed element of the blood and the therapeutic agent, wherein the binding moiety is an antibody or antigen-binding fragment thereof having specificity for glycoprotein IIb/IIIa, said antibody or fragment having the epitopic specificity of murine monoclonal antibody 7E3 and the therapeutic agent is not a thrombolytic agent.
A bioconjugate pair suitable for sustained delivery of a therapeutic agent to the circulation of a patient comprising:
- a) a first bioconjugate comprising a binding moiety which selectively binds to a suspended formed element of the blood and a capture moiety, wherein said binding moiety is a chimeric 7E3 antibody or an antigen-binding fragment thereof and said capture moiety comprises a binding site for a complementary binding partner;
- and
- b) a second bioconjugate comprising the complementary binding partner and the therapeutic agent.
A bioconjugate pair suitable for sustained delivery of a therapeutic agent to the circulation of a patient comprising:
- a) a first bioconjugate comprising a binding moiety which selectively binds to a suspended formed element of the blood and a capture moiety, wherein said binding moiety is a chimeric 7E3 Fab or Fab′ fragment and said capture moiety comprises a binding site for a complementary binding partner;
- and
- b) a second bioconjugate comprising the complementary binding partner and the therapeutic agent.
A bioconjugate pair suitable for sustained delivery of a therapeutic agent to the circulation of a patient comprising:
- a) a first bioconjugate comprising a binding moiety which selectively binds to a suspended formed element of the blood and a capture moiety, wherein said binding moiety is an antibody or antigen-binding fragment thereof having specificity for glycoprotein IIb/IIIa, said antibody or fragment having the epitopic specificity of murine monoclonal antibody 7E3 and said capture moiety comprises a binding site for a complementary binding partner;
- and
- b) a second bioconjugate comprising the complementary binding partner and the therapeutic agent.
A method of preparing a bioconjugate pair for sustained delivery of a therapeutic agent to the circulation of a patient comprising the steps of:
- a) conjugating a binding moiety which selectively binds to a suspended formed element of the blood to a capture moiety, wherein said binding moiety is a chimeric 7E3 antibody or an antigen-binding fragment thereof and said capture moiety comprises a binding site for a complementary binding partner, thereby producing a first bioconjugate;
- b) conjugating the complementary binding partner to the therapeutic agent, thereby producing a second bioconjugate;
- and
- c) screening said bioconjugate pair for sustained delivery of the therapeutic agent,
- whereby a bioconjugate pair for sustained delivery of said therapeutic agent to the circulation of a patient is produced.
A method of preparing a bioconjugate pair for sustained delivery of a therapeutic agent to the circulation of a patient comprising the steps of:
- a) conjugating a binding moiety which selectively binds to a suspended formed element of the blood to a capture moiety, wherein said binding moiety is a chimeric 7E3 Fab or Fab′ fragment and said capture moiety comprises a binding site for a complementary binding partner, thereby producing a first bioconjugate;
- b) conjugating the complementary binding partner to the therapeutic agent, thereby producing a second bioconjugate;
- and
- c) screening said bioconjugate pair for sustained delivery of the therapeutic agent,
- whereby a bioconjugate pair for sustained delivery of said therapeutic agent to the circulation of a patient is produced.
A method of preparing a bioconjugate pair for sustained delivery of a therapeutic agent to the circulation of a patient comprising the steps of:
- a) conjugating a binding moiety which selectively binds to a suspended formed element of the blood to a capture moiety, wherein said binding moiety is an antibody or antigen-binding fragment thereof having specificity for glycoprotein IIb/IIIa, said antibody or fragment having the epitopic specificity of murine monoclonal antibody 7E3 and said capture moiety comprises a binding site for a complementary binding partner, thereby producing a first bioconjugate;
- b) conjugating the complementary binding partner to the therapeutic agent, thereby producing a second bioconjugate;
- and
- c) screening said bioconjugate pair for sustained delivery of the therapeutic agent,
- whereby a bioconjugate pair for sustained delivery of said therapeutic agent to the circulation of a patient is produced.
Dependencies are inferred from the claim text.